Page Title
Drug Development Pipeline
Vanzacaftor + tezacaftor + deutivacaftor (Alyftrek)
Status
To PatientsTherapeutic Approach
Restore CFTR Protein
Vanzacaftor + tezacaftor + deutivacaftor (Alyftrek) is a once-a-day combination therapy combining three CFTR modulators. Vanzacaftor (VX-121) and tezacaftor are CFTR correctors, a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Deutivacaftor is a modified form of ivacaftor that allows Alyftrek to be taken once a day. Ivacaftor is a potentiator that facilitates the opening of the chloride channel on the cell surface to allow chloride and sodium (salt) to move in and out of the cell.
Status
Alyftrek has been approved for people with CF ages 6 and older who are eligible to take Trikafta or have one of 31 specified rare mutations. (Esta lista de mutaciones también está disponible en español).
A Phase 3 study to test the safety of Alyftrek in children with CF ages 2-5 is currently underway.
Sponsor
This program is sponsored by Vertex Pharmaceuticals. This program is being conducted within the Therapeutics Development Network (TDN).
Recent Vanzacaftor + tezacaftor + deutivacaftor (Alyftrek) Studies
-
Closed to Enrollment
Study of VX-121 in people with CF ages 12 years and older who have either two copies of the F508del mutation, one copy of the F508del mutation and one copy of a gating or residual function mutation, or no copies of the F508del mutation and at least one other triple combination responsive CFTR mutation (Vertex VX20-121-103)

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More